Statins and Safety: What the Data Say About Dementia, Cancer, and More
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
Target in Sight: Escalating Therapy to Reach LDL-C Goals
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
Bridging ASCVD Care Between Academic and Rural Settings
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
prof. Hiddo Heerspink
Jennifer B. Green, MD
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Akshay S. Desai, MD
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Jonathan Cunningham, MD
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
John Ostrominski
FINE-HEART Pooled Analysis
Maria Pabon
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.